GMDA
Price
$0.34
Change
-$0.02 (-5.56%)
Updated
Feb 23, 6:59 PM EST
2 days until earnings call
SABS
Price
$4.90
Change
-$0.08 (-1.61%)
Updated
Feb 23, 6:59 PM EST
32 days until earnings call
Ad is loading...

Analysis and predictions GMDA vs SABS

Header iconGMDA vs SABS Comparison
Open Charts GMDA vs SABSBanner chart's image
Gamida Cell
Price$0.34
Change-$0.02 (-5.56%)
Volume$2.12M
CapitalizationN/A
SAB Biotherapeutics
Price$4.90
Change-$0.08 (-1.61%)
Volume$6.6K
CapitalizationN/A
View a ticker or compare two or three
GMDA vs SABS Comparison Chart

Loading...

GMDADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SABSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
GMDA vs. SABS commentary
Feb 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMDA is a Hold and SABS is a Hold.

COMPARISON
Comparison
Feb 25, 2024
Stock price -- (GMDA: $0.34 vs. SABS: $4.96)
Brand notoriety: GMDA and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMDA: 102% vs. SABS: 72%
Market capitalization -- GMDA: $44.85M vs. SABS: $45.76M
GMDA [@Biotechnology] is valued at $44.85M. SABS’s [@Biotechnology] market capitalization is $45.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMDA’s FA Score shows that 0 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • GMDA’s FA Score: 0 green, 5 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, both GMDA and SABS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMDA’s TA Score shows that 5 TA indicator(s) are bullish while SABS’s TA Score has 3 bullish TA indicator(s).

  • GMDA’s TA Score: 5 bullish, 4 bearish.
  • SABS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GMDA is a better buy in the short-term than SABS.

Price Growth

GMDA (@Biotechnology) experienced а -16.93% price change this week, while SABS (@Biotechnology) price change was -9.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

GMDA is expected to report earnings on May 07, 2024.

SABS is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for GMDA with price predictions.
OPEN
A.I.dvisor published
a Summary for SABS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SABS($45.8M) and GMDA($44.8M) have the same market capitalization . GMDA YTD gains are higher at: -18.076 vs. SABS (-27.855). SABS has higher annual earnings (EBITDA): -23.14M vs. GMDA (-75.91M). GMDA has more cash in the bank: 60.4M vs. SABS (2.43M). SABS has less debt than GMDA: SABS (4.65M) vs GMDA (85.2M). GMDA has higher revenues than SABS: GMDA (673K) vs SABS (0).
GMDASABSGMDA / SABS
Capitalization44.8M45.8M98%
EBITDA-75.91M-23.14M328%
Gain YTD-18.076-27.85565%
P/E RatioN/A9.71-
Revenue673K0-
Total Cash60.4M2.43M2,491%
Total Debt85.2M4.65M1,831%
TECHNICAL ANALYSIS
Technical Analysis
GMDASABS
RSI
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
73%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Ad is loading...
GMDADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SABSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LESL7.390.49
+7.10%
Leslie's
AAN10.540.35
+3.43%
Aaron's Company (The)
BXSL29.770.23
+0.78%
Blackstone Secured Lending Fund
ACXP3.150.02
+0.64%
Acurx Pharmaceuticals
CVS77.200.10
+0.13%
CVS HEALTH Corp

GMDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMDA has been loosely correlated with UBX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if GMDA jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMDA
1D Price
Change %
GMDA100%
-5.69%
UBX - GMDA
45%
Loosely correlated
+0.56%
ORMP - GMDA
35%
Loosely correlated
+4.85%
ALXO - GMDA
35%
Loosely correlated
-1.25%
HUMA - GMDA
34%
Loosely correlated
+0.58%
AXON - GMDA
33%
Loosely correlated
-0.34%
More

SABS and

Correlation & Price change

A.I.dvisor tells us that SABS and HOOK have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SABS and HOOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
+1.02%
HOOK - SABS
30%
Poorly correlated
-2.42%
RLAY - SABS
27%
Poorly correlated
-5.39%
NKTX - SABS
25%
Poorly correlated
+1.05%
EFTR - SABS
24%
Poorly correlated
+0.68%
JAGX - SABS
24%
Poorly correlated
+5.26%
More